Independent Digital Biomarker Evaluation

Independent Reliability Evaluation
for Digital Biomarkers

We conduct independent, research-use-only (RUO) evaluations of reproducibility, variability, drift, and failure modes - so you can scale with clarity and evidence.

Book Demo

Why Reliability Fails Most Digital Biomarkers

Biomarkers rarely fail because the model is inaccurate. They fail because real-world behavior is unknown - and pharma partners expect evidence.

You are asked for reproducibility data - your team doesn't have it.
Performance shifts across subjects, devices, or cohorts.
Pharma detects failure modes during due diligence, not R&D.

The Reliability Sprint (4-6 Weeks)

A structured, independent evaluation that pharma teams trust - modeled like a study protocol, not consulting.

Week 1 - Scope

Define biomarker goals, intended use, cohorts, and data requirements.

Weeks 2-4 - Evaluate

Reproducibility analysis, variability profiles, drift detection, failure mode mapping.

Weeks 5-6 - Deliver

You receive a pharma-ready Evidence Pack plus walkthrough.

All evaluations are conducted under a Research Use Only (RUO) model and do not replace clinical validation or regulatory submissions.

De-Risk Your Roadmap. Gain Confidence to Scale.

Your Reliability Sprint can be completed in 4-6 weeks. Move from R&D uncertainty to partner-ready evidence.